非侵襲的ワクチン接種 - 世界市場シェアとランキング、全体売上高と需要予測 2024-2030Noninvasive Vaccination - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 非侵襲的ワクチン送達システムには、粘膜免疫反応と全身免疫反応の両方を誘発するように特別に設計された、効果的なアジュバントを組み込む必要がある。 非侵襲的ワクチン接種の世界市場は、2023年には2億6,000... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー非侵襲的ワクチン送達システムには、粘膜免疫反応と全身免疫反応の両方を誘発するように特別に設計された、効果的なアジュバントを組み込む必要がある。非侵襲的ワクチン接種の世界市場は、2023年には2億6,000万米ドルと推定され、2024-2030年の予測期間中のCAGRは5.6%で、2030年には3億9,091万米ドルに再調整されると予測されている。 経口ワクチン市場は、従来の注射ワクチンに比べ、投与が容易で、患者のコンプライアンスが向上し、費用対効果が高いという利点が主な要因です。経口ワクチンは非侵襲的で痛みを伴わない予防接種方法であり、特に小児や高齢者にとっては有益である。さらに、全身免疫と粘膜免疫の両方を誘発する可能性があるため、呼吸器や消化管などの粘膜表面から体内に侵入する病原体に対する防御が強化され、その採用がさらに加速している。しかしながら、経口ワクチンの複雑な製剤化や送達など、安定性や有効性に影響を及ぼす可能性のある課題にも直面している。酸性環境や消化管内での酵素分解に耐えるワクチンの開発には、科学的・製造的に大きな課題がある。さらに、規制当局の承認を得たり、経口ワクチンを一般に受け入れられるようにするには、広範な臨床データや、安全性や有効性に関する誤解を払拭するための啓蒙活動が必要になることもあります。これらの課題を克服するため、業界は経口ワクチンの製剤化および送達技術を改善するための研究と技術革新に注力しています。ワクチン開発企業、研究機関、規制当局の協力は、経口ワクチン市場の成長を促進し、特に医療インフラが限られている地域において、効果的で利用しやすい予防接種オプションへのアクセスを拡大する上で極めて重要である。 レポートの範囲 本レポートでは、非侵襲的ワクチン接種の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総販売量、販売収益、価格、主要企業の市場シェア、ランキングに焦点を当て、包括的なプレゼンテーションを提供することを目的としています。 非侵襲的ワクチン接種の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データおよび予測データとともに、販売数量(K単位)および販売収益(百万ドル)で提供されます。定量分析および定性分析により、読者が事業/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、非侵襲的ワクチン接種に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 メルク GSK サノフィ 蘭州研究所 血清研究所 バルネバ 上海ユナイテッドセル ビブコル パックスバックス バビオテック 天壇生物 ユーバイオロジクス パナセアバイオテック バイオメッド ハーフキン・バイオファーマシューティカルズ アストラゼネカ シプラ BCHT タイプ別セグメント 経口ワクチン 経鼻スプレーワクチン 用途別セグメント 公共 民間 地域別 北米 米国 カナダ ヨーロッパ ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章: レポートの対象範囲、世界の総市場規模(バルブ、数量、価格)を紹介。この章ではまた、市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章:非侵襲性ワクチン接種メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章:タイプ別に様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのを助ける。 第4章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる川下市場のブルーオーシャン市場を見つけるのに役立ちます。 第5章:地域レベルでの非侵襲的ワクチン接種の売上高、収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章 国別非侵襲的ワクチン接種の売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章:主要企業のプロファイルを提供し、製品の売上高、収益、価格、粗利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。 第8章:産業の上流と下流を含む産業チェーンの分析。 第9章:結論 目次1 Market Overview1.1 Noninvasive Vaccination Product Introduction 1.2 Global Noninvasive Vaccination Market Size Forecast 1.2.1 Global Noninvasive Vaccination Sales Value (2019-2030) 1.2.2 Global Noninvasive Vaccination Sales Volume (2019-2030) 1.2.3 Global Noninvasive Vaccination Sales Price (2019-2030) 1.3 Noninvasive Vaccination Market Trends & Drivers 1.3.1 Noninvasive Vaccination Industry Trends 1.3.2 Noninvasive Vaccination Market Drivers & Opportunity 1.3.3 Noninvasive Vaccination Market Challenges 1.3.4 Noninvasive Vaccination Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Noninvasive Vaccination Players Revenue Ranking (2023) 2.2 Global Noninvasive Vaccination Revenue by Company (2019-2024) 2.3 Global Noninvasive Vaccination Players Sales Volume Ranking (2023) 2.4 Global Noninvasive Vaccination Sales Volume by Company Players (2019-2024) 2.5 Global Noninvasive Vaccination Average Price by Company (2019-2024) 2.6 Key Manufacturers Noninvasive Vaccination Manufacturing Base Distribution and Headquarters 2.7 Key Manufacturers Noninvasive Vaccination Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Noninvasive Vaccination 2.9 Noninvasive Vaccination Market Competitive Analysis 2.9.1 Noninvasive Vaccination Market Concentration Rate (2019-2024) 2.9.2 Global 5 and 10 Largest Manufacturers by Noninvasive Vaccination Revenue in 2023 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Vaccination as of 2023) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Oral Vaccine 3.1.2 Nasal Spray Vaccine 3.2 Global Noninvasive Vaccination Sales Value by Type 3.2.1 Global Noninvasive Vaccination Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Noninvasive Vaccination Sales Value, by Type (2019-2030) 3.2.3 Global Noninvasive Vaccination Sales Value, by Type (%) (2019-2030) 3.3 Global Noninvasive Vaccination Sales Volume by Type 3.3.1 Global Noninvasive Vaccination Sales Volume by Type (2019 VS 2023 VS 2030) 3.3.2 Global Noninvasive Vaccination Sales Volume, by Type (2019-2030) 3.3.3 Global Noninvasive Vaccination Sales Volume, by Type (%) (2019-2030) 3.4 Global Noninvasive Vaccination Average Price by Type (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Public 4.1.2 Private 4.2 Global Noninvasive Vaccination Sales Value by Application 4.2.1 Global Noninvasive Vaccination Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Noninvasive Vaccination Sales Value, by Application (2019-2030) 4.2.3 Global Noninvasive Vaccination Sales Value, by Application (%) (2019-2030) 4.3 Global Noninvasive Vaccination Sales Volume by Application 4.3.1 Global Noninvasive Vaccination Sales Volume by Application (2019 VS 2023 VS 2030) 4.3.2 Global Noninvasive Vaccination Sales Volume, by Application (2019-2030) 4.3.3 Global Noninvasive Vaccination Sales Volume, by Application (%) (2019-2030) 4.4 Global Noninvasive Vaccination Average Price by Application (2019-2030) 5 Segmentation by Region 5.1 Global Noninvasive Vaccination Sales Value by Region 5.1.1 Global Noninvasive Vaccination Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Noninvasive Vaccination Sales Value by Region (2019-2024) 5.1.3 Global Noninvasive Vaccination Sales Value by Region (2025-2030) 5.1.4 Global Noninvasive Vaccination Sales Value by Region (%), (2019-2030) 5.2 Global Noninvasive Vaccination Sales Volume by Region 5.2.1 Global Noninvasive Vaccination Sales Volume by Region: 2019 VS 2023 VS 2030 5.2.2 Global Noninvasive Vaccination Sales Volume by Region (2019-2024) 5.2.3 Global Noninvasive Vaccination Sales Volume by Region (2025-2030) 5.2.4 Global Noninvasive Vaccination Sales Volume by Region (%), (2019-2030) 5.3 Global Noninvasive Vaccination Average Price by Region (2019-2030) 5.4 North America 5.4.1 North America Noninvasive Vaccination Sales Value, 2019-2030 5.4.2 North America Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 5.5 Europe 5.5.1 Europe Noninvasive Vaccination Sales Value, 2019-2030 5.5.2 Europe Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 5.6 Asia Pacific 5.6.1 Asia Pacific Noninvasive Vaccination Sales Value, 2019-2030 5.6.2 Asia Pacific Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 5.7 South America 5.7.1 South America Noninvasive Vaccination Sales Value, 2019-2030 5.7.2 South America Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 5.8 Middle East & Africa 5.8.1 Middle East & Africa Noninvasive Vaccination Sales Value, 2019-2030 5.8.2 Middle East & Africa Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Noninvasive Vaccination Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Noninvasive Vaccination Sales Value 6.2.1 Key Countries/Regions Noninvasive Vaccination Sales Value, 2019-2030 6.2.2 Key Countries/Regions Noninvasive Vaccination Sales Volume, 2019-2030 6.3 United States 6.3.1 United States Noninvasive Vaccination Sales Value, 2019-2030 6.3.2 United States Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Noninvasive Vaccination Sales Value, 2019-2030 6.4.2 Europe Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Noninvasive Vaccination Sales Value, 2019-2030 6.5.2 China Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.5.3 China Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Noninvasive Vaccination Sales Value, 2019-2030 6.6.2 Japan Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Noninvasive Vaccination Sales Value, 2019-2030 6.7.2 South Korea Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Noninvasive Vaccination Sales Value, 2019-2030 6.8.2 Southeast Asia Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Noninvasive Vaccination Sales Value, 2019-2030 6.9.2 India Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.9.3 India Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Merck 7.1.1 Merck Company Information 7.1.2 Merck Introduction and Business Overview 7.1.3 Merck Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.1.4 Merck Noninvasive Vaccination Product Offerings 7.1.5 Merck Recent Development 7.2 GSK 7.2.1 GSK Company Information 7.2.2 GSK Introduction and Business Overview 7.2.3 GSK Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.2.4 GSK Noninvasive Vaccination Product Offerings 7.2.5 GSK Recent Development 7.3 Sanofi 7.3.1 Sanofi Company Information 7.3.2 Sanofi Introduction and Business Overview 7.3.3 Sanofi Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.3.4 Sanofi Noninvasive Vaccination Product Offerings 7.3.5 Sanofi Recent Development 7.4 Lanzhou Institute 7.4.1 Lanzhou Institute Company Information 7.4.2 Lanzhou Institute Introduction and Business Overview 7.4.3 Lanzhou Institute Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.4.4 Lanzhou Institute Noninvasive Vaccination Product Offerings 7.4.5 Lanzhou Institute Recent Development 7.5 Serum Institute 7.5.1 Serum Institute Company Information 7.5.2 Serum Institute Introduction and Business Overview 7.5.3 Serum Institute Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.5.4 Serum Institute Noninvasive Vaccination Product Offerings 7.5.5 Serum Institute Recent Development 7.6 Valneva 7.6.1 Valneva Company Information 7.6.2 Valneva Introduction and Business Overview 7.6.3 Valneva Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.6.4 Valneva Noninvasive Vaccination Product Offerings 7.6.5 Valneva Recent Development 7.7 Shanghai United Cell 7.7.1 Shanghai United Cell Company Information 7.7.2 Shanghai United Cell Introduction and Business Overview 7.7.3 Shanghai United Cell Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.7.4 Shanghai United Cell Noninvasive Vaccination Product Offerings 7.7.5 Shanghai United Cell Recent Development 7.8 Bibcol 7.8.1 Bibcol Company Information 7.8.2 Bibcol Introduction and Business Overview 7.8.3 Bibcol Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.8.4 Bibcol Noninvasive Vaccination Product Offerings 7.8.5 Bibcol Recent Development 7.9 PaxVax 7.9.1 PaxVax Company Information 7.9.2 PaxVax Introduction and Business Overview 7.9.3 PaxVax Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.9.4 PaxVax Noninvasive Vaccination Product Offerings 7.9.5 PaxVax Recent Development 7.10 Vabiotech 7.10.1 Vabiotech Company Information 7.10.2 Vabiotech Introduction and Business Overview 7.10.3 Vabiotech Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.10.4 Vabiotech Noninvasive Vaccination Product Offerings 7.10.5 Vabiotech Recent Development 7.11 Tiantan Biological 7.11.1 Tiantan Biological Company Information 7.11.2 Tiantan Biological Introduction and Business Overview 7.11.3 Tiantan Biological Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.11.4 Tiantan Biological Noninvasive Vaccination Product Offerings 7.11.5 Tiantan Biological Recent Development 7.12 EuBiologics 7.12.1 EuBiologics Company Information 7.12.2 EuBiologics Introduction and Business Overview 7.12.3 EuBiologics Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.12.4 EuBiologics Noninvasive Vaccination Product Offerings 7.12.5 EuBiologics Recent Development 7.13 Panacea Biotec Ltd 7.13.1 Panacea Biotec Ltd Company Information 7.13.2 Panacea Biotec Ltd Introduction and Business Overview 7.13.3 Panacea Biotec Ltd Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.13.4 Panacea Biotec Ltd Noninvasive Vaccination Product Offerings 7.13.5 Panacea Biotec Ltd Recent Development 7.14 Bio-Med 7.14.1 Bio-Med Company Information 7.14.2 Bio-Med Introduction and Business Overview 7.14.3 Bio-Med Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.14.4 Bio-Med Noninvasive Vaccination Product Offerings 7.14.5 Bio-Med Recent Development 7.15 Halfkin Bio-Pharmaceuticals 7.15.1 Halfkin Bio-Pharmaceuticals Company Information 7.15.2 Halfkin Bio-Pharmaceuticals Introduction and Business Overview 7.15.3 Halfkin Bio-Pharmaceuticals Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.15.4 Halfkin Bio-Pharmaceuticals Noninvasive Vaccination Product Offerings 7.15.5 Halfkin Bio-Pharmaceuticals Recent Development 7.16 AstraZeneca 7.16.1 AstraZeneca Company Information 7.16.2 AstraZeneca Introduction and Business Overview 7.16.3 AstraZeneca Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.16.4 AstraZeneca Noninvasive Vaccination Product Offerings 7.16.5 AstraZeneca Recent Development 7.17 Cipla 7.17.1 Cipla Company Information 7.17.2 Cipla Introduction and Business Overview 7.17.3 Cipla Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.17.4 Cipla Noninvasive Vaccination Product Offerings 7.17.5 Cipla Recent Development 7.18 BCHT 7.18.1 BCHT Company Information 7.18.2 BCHT Introduction and Business Overview 7.18.3 BCHT Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.18.4 BCHT Noninvasive Vaccination Product Offerings 7.18.5 BCHT Recent Development 8 Industry Chain Analysis 8.1 Noninvasive Vaccination Industrial Chain 8.2 Noninvasive Vaccination Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Noninvasive Vaccination Sales Model 8.5.2 Sales Channel 8.5.3 Noninvasive Vaccination Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryNoninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses. Table of Contents1 Market Overview1.1 Noninvasive Vaccination Product Introduction 1.2 Global Noninvasive Vaccination Market Size Forecast 1.2.1 Global Noninvasive Vaccination Sales Value (2019-2030) 1.2.2 Global Noninvasive Vaccination Sales Volume (2019-2030) 1.2.3 Global Noninvasive Vaccination Sales Price (2019-2030) 1.3 Noninvasive Vaccination Market Trends & Drivers 1.3.1 Noninvasive Vaccination Industry Trends 1.3.2 Noninvasive Vaccination Market Drivers & Opportunity 1.3.3 Noninvasive Vaccination Market Challenges 1.3.4 Noninvasive Vaccination Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Noninvasive Vaccination Players Revenue Ranking (2023) 2.2 Global Noninvasive Vaccination Revenue by Company (2019-2024) 2.3 Global Noninvasive Vaccination Players Sales Volume Ranking (2023) 2.4 Global Noninvasive Vaccination Sales Volume by Company Players (2019-2024) 2.5 Global Noninvasive Vaccination Average Price by Company (2019-2024) 2.6 Key Manufacturers Noninvasive Vaccination Manufacturing Base Distribution and Headquarters 2.7 Key Manufacturers Noninvasive Vaccination Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Noninvasive Vaccination 2.9 Noninvasive Vaccination Market Competitive Analysis 2.9.1 Noninvasive Vaccination Market Concentration Rate (2019-2024) 2.9.2 Global 5 and 10 Largest Manufacturers by Noninvasive Vaccination Revenue in 2023 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Vaccination as of 2023) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Oral Vaccine 3.1.2 Nasal Spray Vaccine 3.2 Global Noninvasive Vaccination Sales Value by Type 3.2.1 Global Noninvasive Vaccination Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Noninvasive Vaccination Sales Value, by Type (2019-2030) 3.2.3 Global Noninvasive Vaccination Sales Value, by Type (%) (2019-2030) 3.3 Global Noninvasive Vaccination Sales Volume by Type 3.3.1 Global Noninvasive Vaccination Sales Volume by Type (2019 VS 2023 VS 2030) 3.3.2 Global Noninvasive Vaccination Sales Volume, by Type (2019-2030) 3.3.3 Global Noninvasive Vaccination Sales Volume, by Type (%) (2019-2030) 3.4 Global Noninvasive Vaccination Average Price by Type (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Public 4.1.2 Private 4.2 Global Noninvasive Vaccination Sales Value by Application 4.2.1 Global Noninvasive Vaccination Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Noninvasive Vaccination Sales Value, by Application (2019-2030) 4.2.3 Global Noninvasive Vaccination Sales Value, by Application (%) (2019-2030) 4.3 Global Noninvasive Vaccination Sales Volume by Application 4.3.1 Global Noninvasive Vaccination Sales Volume by Application (2019 VS 2023 VS 2030) 4.3.2 Global Noninvasive Vaccination Sales Volume, by Application (2019-2030) 4.3.3 Global Noninvasive Vaccination Sales Volume, by Application (%) (2019-2030) 4.4 Global Noninvasive Vaccination Average Price by Application (2019-2030) 5 Segmentation by Region 5.1 Global Noninvasive Vaccination Sales Value by Region 5.1.1 Global Noninvasive Vaccination Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Noninvasive Vaccination Sales Value by Region (2019-2024) 5.1.3 Global Noninvasive Vaccination Sales Value by Region (2025-2030) 5.1.4 Global Noninvasive Vaccination Sales Value by Region (%), (2019-2030) 5.2 Global Noninvasive Vaccination Sales Volume by Region 5.2.1 Global Noninvasive Vaccination Sales Volume by Region: 2019 VS 2023 VS 2030 5.2.2 Global Noninvasive Vaccination Sales Volume by Region (2019-2024) 5.2.3 Global Noninvasive Vaccination Sales Volume by Region (2025-2030) 5.2.4 Global Noninvasive Vaccination Sales Volume by Region (%), (2019-2030) 5.3 Global Noninvasive Vaccination Average Price by Region (2019-2030) 5.4 North America 5.4.1 North America Noninvasive Vaccination Sales Value, 2019-2030 5.4.2 North America Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 5.5 Europe 5.5.1 Europe Noninvasive Vaccination Sales Value, 2019-2030 5.5.2 Europe Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 5.6 Asia Pacific 5.6.1 Asia Pacific Noninvasive Vaccination Sales Value, 2019-2030 5.6.2 Asia Pacific Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 5.7 South America 5.7.1 South America Noninvasive Vaccination Sales Value, 2019-2030 5.7.2 South America Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 5.8 Middle East & Africa 5.8.1 Middle East & Africa Noninvasive Vaccination Sales Value, 2019-2030 5.8.2 Middle East & Africa Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Noninvasive Vaccination Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Noninvasive Vaccination Sales Value 6.2.1 Key Countries/Regions Noninvasive Vaccination Sales Value, 2019-2030 6.2.2 Key Countries/Regions Noninvasive Vaccination Sales Volume, 2019-2030 6.3 United States 6.3.1 United States Noninvasive Vaccination Sales Value, 2019-2030 6.3.2 United States Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Noninvasive Vaccination Sales Value, 2019-2030 6.4.2 Europe Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Noninvasive Vaccination Sales Value, 2019-2030 6.5.2 China Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.5.3 China Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Noninvasive Vaccination Sales Value, 2019-2030 6.6.2 Japan Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Noninvasive Vaccination Sales Value, 2019-2030 6.7.2 South Korea Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Noninvasive Vaccination Sales Value, 2019-2030 6.8.2 Southeast Asia Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Noninvasive Vaccination Sales Value, 2019-2030 6.9.2 India Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030 6.9.3 India Noninvasive Vaccination Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Merck 7.1.1 Merck Company Information 7.1.2 Merck Introduction and Business Overview 7.1.3 Merck Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.1.4 Merck Noninvasive Vaccination Product Offerings 7.1.5 Merck Recent Development 7.2 GSK 7.2.1 GSK Company Information 7.2.2 GSK Introduction and Business Overview 7.2.3 GSK Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.2.4 GSK Noninvasive Vaccination Product Offerings 7.2.5 GSK Recent Development 7.3 Sanofi 7.3.1 Sanofi Company Information 7.3.2 Sanofi Introduction and Business Overview 7.3.3 Sanofi Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.3.4 Sanofi Noninvasive Vaccination Product Offerings 7.3.5 Sanofi Recent Development 7.4 Lanzhou Institute 7.4.1 Lanzhou Institute Company Information 7.4.2 Lanzhou Institute Introduction and Business Overview 7.4.3 Lanzhou Institute Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.4.4 Lanzhou Institute Noninvasive Vaccination Product Offerings 7.4.5 Lanzhou Institute Recent Development 7.5 Serum Institute 7.5.1 Serum Institute Company Information 7.5.2 Serum Institute Introduction and Business Overview 7.5.3 Serum Institute Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.5.4 Serum Institute Noninvasive Vaccination Product Offerings 7.5.5 Serum Institute Recent Development 7.6 Valneva 7.6.1 Valneva Company Information 7.6.2 Valneva Introduction and Business Overview 7.6.3 Valneva Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.6.4 Valneva Noninvasive Vaccination Product Offerings 7.6.5 Valneva Recent Development 7.7 Shanghai United Cell 7.7.1 Shanghai United Cell Company Information 7.7.2 Shanghai United Cell Introduction and Business Overview 7.7.3 Shanghai United Cell Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.7.4 Shanghai United Cell Noninvasive Vaccination Product Offerings 7.7.5 Shanghai United Cell Recent Development 7.8 Bibcol 7.8.1 Bibcol Company Information 7.8.2 Bibcol Introduction and Business Overview 7.8.3 Bibcol Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.8.4 Bibcol Noninvasive Vaccination Product Offerings 7.8.5 Bibcol Recent Development 7.9 PaxVax 7.9.1 PaxVax Company Information 7.9.2 PaxVax Introduction and Business Overview 7.9.3 PaxVax Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.9.4 PaxVax Noninvasive Vaccination Product Offerings 7.9.5 PaxVax Recent Development 7.10 Vabiotech 7.10.1 Vabiotech Company Information 7.10.2 Vabiotech Introduction and Business Overview 7.10.3 Vabiotech Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.10.4 Vabiotech Noninvasive Vaccination Product Offerings 7.10.5 Vabiotech Recent Development 7.11 Tiantan Biological 7.11.1 Tiantan Biological Company Information 7.11.2 Tiantan Biological Introduction and Business Overview 7.11.3 Tiantan Biological Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.11.4 Tiantan Biological Noninvasive Vaccination Product Offerings 7.11.5 Tiantan Biological Recent Development 7.12 EuBiologics 7.12.1 EuBiologics Company Information 7.12.2 EuBiologics Introduction and Business Overview 7.12.3 EuBiologics Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.12.4 EuBiologics Noninvasive Vaccination Product Offerings 7.12.5 EuBiologics Recent Development 7.13 Panacea Biotec Ltd 7.13.1 Panacea Biotec Ltd Company Information 7.13.2 Panacea Biotec Ltd Introduction and Business Overview 7.13.3 Panacea Biotec Ltd Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.13.4 Panacea Biotec Ltd Noninvasive Vaccination Product Offerings 7.13.5 Panacea Biotec Ltd Recent Development 7.14 Bio-Med 7.14.1 Bio-Med Company Information 7.14.2 Bio-Med Introduction and Business Overview 7.14.3 Bio-Med Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.14.4 Bio-Med Noninvasive Vaccination Product Offerings 7.14.5 Bio-Med Recent Development 7.15 Halfkin Bio-Pharmaceuticals 7.15.1 Halfkin Bio-Pharmaceuticals Company Information 7.15.2 Halfkin Bio-Pharmaceuticals Introduction and Business Overview 7.15.3 Halfkin Bio-Pharmaceuticals Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.15.4 Halfkin Bio-Pharmaceuticals Noninvasive Vaccination Product Offerings 7.15.5 Halfkin Bio-Pharmaceuticals Recent Development 7.16 AstraZeneca 7.16.1 AstraZeneca Company Information 7.16.2 AstraZeneca Introduction and Business Overview 7.16.3 AstraZeneca Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.16.4 AstraZeneca Noninvasive Vaccination Product Offerings 7.16.5 AstraZeneca Recent Development 7.17 Cipla 7.17.1 Cipla Company Information 7.17.2 Cipla Introduction and Business Overview 7.17.3 Cipla Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.17.4 Cipla Noninvasive Vaccination Product Offerings 7.17.5 Cipla Recent Development 7.18 BCHT 7.18.1 BCHT Company Information 7.18.2 BCHT Introduction and Business Overview 7.18.3 BCHT Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024) 7.18.4 BCHT Noninvasive Vaccination Product Offerings 7.18.5 BCHT Recent Development 8 Industry Chain Analysis 8.1 Noninvasive Vaccination Industrial Chain 8.2 Noninvasive Vaccination Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Noninvasive Vaccination Sales Model 8.5.2 Sales Channel 8.5.3 Noninvasive Vaccination Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート本レポートと同じKEY WORD(vaccination)の最新刊レポートよくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|